1. Home
  2. IOTR vs SCYX Comparison

IOTR vs SCYX Comparison

Compare IOTR & SCYX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • IOTR
  • SCYX
  • Stock Information
  • Founded
  • IOTR 2019
  • SCYX 1999
  • Country
  • IOTR Singapore
  • SCYX United States
  • Employees
  • IOTR N/A
  • SCYX N/A
  • Industry
  • IOTR
  • SCYX Biotechnology: Pharmaceutical Preparations
  • Sector
  • IOTR
  • SCYX Health Care
  • Exchange
  • IOTR NYSE
  • SCYX Nasdaq
  • Market Cap
  • IOTR 11.5M
  • SCYX 28.5M
  • IPO Year
  • IOTR 2025
  • SCYX 2014
  • Fundamental
  • Price
  • IOTR $0.47
  • SCYX $0.70
  • Analyst Decision
  • IOTR
  • SCYX
  • Analyst Count
  • IOTR 0
  • SCYX 0
  • Target Price
  • IOTR N/A
  • SCYX N/A
  • AVG Volume (30 Days)
  • IOTR 693.0K
  • SCYX 187.5K
  • Earning Date
  • IOTR 01-01-0001
  • SCYX 08-11-2025
  • Dividend Yield
  • IOTR N/A
  • SCYX N/A
  • EPS Growth
  • IOTR N/A
  • SCYX N/A
  • EPS
  • IOTR N/A
  • SCYX N/A
  • Revenue
  • IOTR $10,478,550.00
  • SCYX $2,630,000.00
  • Revenue This Year
  • IOTR N/A
  • SCYX $410.22
  • Revenue Next Year
  • IOTR N/A
  • SCYX $248.83
  • P/E Ratio
  • IOTR N/A
  • SCYX N/A
  • Revenue Growth
  • IOTR 22.27
  • SCYX N/A
  • 52 Week Low
  • IOTR $0.31
  • SCYX $0.66
  • 52 Week High
  • IOTR $5.98
  • SCYX $2.21
  • Technical
  • Relative Strength Index (RSI)
  • IOTR N/A
  • SCYX 41.70
  • Support Level
  • IOTR N/A
  • SCYX $0.67
  • Resistance Level
  • IOTR N/A
  • SCYX $0.74
  • Average True Range (ATR)
  • IOTR 0.00
  • SCYX 0.04
  • MACD
  • IOTR 0.00
  • SCYX 0.00
  • Stochastic Oscillator
  • IOTR 0.00
  • SCYX 10.15

About IOTR IOTHREE LIMITED

iOThree Ltd is a provider of maritime digital technologies, including satellite connectivity and digitalization solutions in Singapore, focused on facilitating the maritime industry towards digital transformation. It offers shipboard infrastructure to customers by designing and installing the necessary satellite connectivity solution, IT equipment, shipboard equipment (such as equipment relating to navigation systems, automatic identification system, etc.), and JARVISS, a digitalization platform on the vessels of customers. The group's operating segments are: Satellite connectivity solution, which generates key revenue, and Digitalization and other solution. Geographically, it generates maximum revenue from Singapore, and rest from Israel, Malaysia, Vietnam, Thailand, and other regions.

About SCYX SCYNEXIS Inc.

SCYNEXIS Inc is a drug development company that focuses on the development and commercialization of novel anti-infectives to address unmet therapeutic needs. It is engaged in developing a product candidate, ibrexafungerp which is a novel oral and intravenous (IV) drug for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections. The ibrexafungerp is a novel and structurally distinct triterpenoid glucan synthase inhibitor that is effective in vitro and in vivo against broad range of Candida and Aspergillus species, including drug-resistant strains as well as Pneumocystis, Coccidioides, Histoplasma and Blastomyces genera and some common mucorales species.

Share on Social Networks: